News
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug
BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization agreement. The pact focuses on BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types.
The Florida State University community mourns the loss of esteemed chemist and noted inventor Robert Holton, whose ...
Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...
BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid ...
As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...
Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the ...
PRINCETON, NJ / ACCESS Newswire / June 6, 2025 / Originally published on University of Kentucky Research NewsA groundbreaking lung cancer screening project co-led by the University of Kentucky Markey ...
Brian Peters started his new role as SVP of the AI Squared division at Apimeds Pharmaceuticals. Pharma market research firm Konovo named Tim Albury as CFO. Tenpoint Therapeutics announced the ...
Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s BNT-327 in a deal possibly worth over $11 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback